HealthQuill Eisai Co
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More
Japan’s Eisai Co., and US-based Biogen Inc., announced its Leqembi injection will be sold in Japan from Japan from December 20, the second country after the US.
Drugs Health Pharma

Eisai, Biogen to sell Alzheimer’s drug in Japan starting December 20 

HQ Team December 13, 2023: Japan’s Eisai Co., and US-based Biogen Inc., announced its Leqembi injection will be sold in Japan from Japan.

Read More
Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for detecting Alzheimer’s disease early.
Drugs Health Pharma

Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s 

HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.

Read More
Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority for leqembi, an investigational drug to treat early onset of Alzheimer’s disease.
Drugs Health Medical Pharma

Japan’s Eisai seeks marketing nod for Alzheimer’s drug in South Korea

HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.

Read More
The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.
Drugs Pharma

FDA gives accelerated approval for Alzheimer’s drug

The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.

Read More